Cepheid, Infectio Diagnostics Inc. deal

The companies terminated their 2000 Aridia Corp. diagnostic joint venture and replaced it with multiple licensing deals (see BioCentury, May 22, 2000). CPHD received non-exclusive global distribution rights to Infectio's assays for Group B Streptococcus (GBS), methicillin resistant staph aureus (MRSA), and vancomycin resistant enterococcus (VRE). The assays are for use with CPHD's Smart Cycler System. Infectio retains exclusive distribution rights for the assays in Canada. The GBS assay is approved in the U.S. and Canada and the MRSA assay is under review. ...